Jaguar Animal Health Inc (JAGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.59M
Last updated: Nov 17, 2026 at 4:26 PM ET
Jaguar Animal Health Inc (JAGX) Statistics
Jaguar Animal Health (JAGX) has a market cap of $5.59M and an enterprise value of $2.55M. Revenue grew 129.74% over the last 12 months from the 12 months before. It kept -122.26% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 54.30% below the market cap, as cash exceeds debt.
| Market Cap | $5.59M |
|---|---|
| Enterprise Value | $2.55M |
| Latest price (Nov 17, 2026) | $0.38 |
Key Dates
The next earnings report is expected on Apr 5, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Apr 5, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 99.90% over 52 weeks and trades 82.88% below its 50-day average.
| Beta (1Y) | 3.83 |
|---|---|
| 52-Week Change | -99.90% |
| 1-Month Change | -86.53% |
| 3-Month Change | -94.52% |
| 6-Month Change | -98.49% |
| 5-Year Change | -100.00% |
| 10-Year Change | -100.00% |
| Total Return (1Y) | -99.90% |
| Total Return (3Y CAGR) | -98.58% |
| Total Return (5Y CAGR) | -97.46% |
| Max Drawdown (1Y) | -99.90% |
| Max Drawdown (3Y) | -100.00% |
| Sharpe Ratio (1Y) | -1.94 |
| Correlation with SPY (1Y) | 0.15 |
| 50-Day Average | $2.22 |
| 200-Day Average | $45.05 |
| 52-Week Range | $0.36 to $981.75 |
| RSI (14 Days) | 36.4 |
| Average Volume (20 Days) | 905.90K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.28x current liabilities, and total debt is 0.12x shareholder equity.
| Current Ratio | 1.28x |
|---|---|
| Quick Ratio | 0.75x |
| Debt / Equity | 0.12x |
| Interest Coverage | -6.04x |
Returns and Efficiency
Return on invested capital is -98.36% over the last 12 months, against a 5-year average of -95.95%.
| Return on Equity (ROE) | -162.90% |
|---|---|
| Return on Assets (ROA) | -101.82% |
| Return on Invested Capital (ROIC) | -98.36% |
| Return on Capital Employed (ROCE) | -144.32% |
| ROA (5Y Average) | -99.53% |
| ROIC (5Y Average) | -95.95% |
| Asset Turnover | 0.66x |
| Inventory Turnover | 0.71x |
| Receivables Turnover | 56.82x |
| Cash Conversion Cycle | 133 days |
Scores
JAGX has an Altman Z-Score of -19.54, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -19.54 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $27.07M over the last 12 months.
| Revenue | $27.07M |
|---|---|
| Revenue Growth (YoY) | +129.74% |
| Gross Profit | $22.06M |
| Operating Income | -$24.68M |
| Pretax Income | -$33.10M |
| Net Income | -$33.10M |
| EBIT | -$28.40M |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 62.50% of the $32.51M in total assets.
| Cash and Equivalents | $5.53M |
|---|---|
| Total Debt | $2.49M |
| Net Cash | $3.04M |
| Net Cash Per Share | $4.43 |
| Working Capital | $3.56M |
| Shareholder Equity | $20.32M |
| Book Value Per Share | $29.69 |
| Tangible Book Value | $5.70M |
| Tangible Book Per Share | $8.33 |
| Total Assets | $32.51M |
| Total Liabilities | $13.89M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$6.92M |
|---|---|
| FCF Per Share | -$0.52 |
| Depreciation and Amortization | $2.89M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -91.15%.
| Gross Margin | 81.47% |
|---|---|
| Operating Margin | -91.15% |
| Pretax Margin | -122.26% |
| Net Margin | -122.26% |
| EBIT Margin | -104.90% |
| Gross Margin (5Y Average) | 71.78% |
Growth
Revenue fell 1.26% a year over 3 years.
| Revenue Growth (3Y CAGR) | -1.26% |
|---|---|
| Revenue Growth (5Y CAGR) | +4.17% |
Dividends and Yields
JAGX does not pay a dividend.
| Buyback Yield | 31.15% |
|---|---|
| Shareholder Yield | 31.15% |
Stock Splits
The last split was a 2-for-1 forward split on Oct 16, 2026.
| Last Split Date | Oct 16, 2026 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 3 similar companies, JAGX has the 2nd highest ROIC.
ROICPeer median -247.19%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -100.00%
| ROIC | -98.36% vs -247.19% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +129.74% vs -100.00% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About JAGX
What is JAGX's market cap?
Jaguar Animal Health has a market cap of $5.59M. Its enterprise value, which adds debt and subtracts cash, is $2.55M.
How many shares of JAGX are outstanding?
Jaguar Animal Health has 684.37K shares outstanding.
Does JAGX pay a dividend?
No. Jaguar Animal Health does not pay a dividend.
How much debt does JAGX have?
Jaguar Animal Health has $2.49M of total debt and $5.53M of cash and equivalents, a net cash position of $3.04M.
JAGX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors